- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (228)
- Breast Cancer (712)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (6)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (98)
- Ovarian Cancer (172)
- Pancreatic Cancer (166)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (294)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (622)
- Complementary Integrative Medicine (22)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (224)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (116)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (880)
- Research (384)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (598)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (324)
- Symptoms (182)
- Treatment (1764)
Racial disparities: An unexplained factor in kidney cancer survival
3 minute read | Published November 12, 2012
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on November 12, 2012
A grimmer prognosis awaits African-Americans when compared to Caucasian patients suffering from renal cell carcinoma (RCC), the most common form of invasive kidney cancer.
In a recent study lead at the National Cancer Institute and published in the Cancer journal, researchers found that African-Americans tend to have a poorer 5-year survival rate than Caucasians regardless of clinical data and patient demographics. "There is a consistent disparity between the races," said Wong-Ho Chow, Ph.D., professor in MD Anderson's Department of Epidemiology and lead investigator on the study.
In this study, clinical data and demographics of nearly 40,000 RCC patients diagnosed over a 15-year period from 12 registries in the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program, were analyzed.
The study revealed the 5-year relative survival rate for Caucasians diagnosed with invasive kidney cancer was 72.6% as compared to 68% for African-Americans regardless of age, sex, tumor size or stage, type of RCC and surgical procedures performed. SEER data also showed a poorer survival rate among men and older patients as compared to women and younger patients. Although research has shown an increase in risk of renal cell carcinoma when linked to hypertension, which disproportionately affects African- Americans, Chow notes that the study did not have appropriate data to investigate if high blood pressure may have contributed to the racial disparity in survival after cancer diagnosis.
The findings suggest that African-Americans not only have higher incidence rates of RCC, but also lower survival rates after RCC diagnosis.
RCC, the most common type of kidney cancer in adults and the most deadly cancer among urological tumors, affects more than 30,000 men and women every year in the United States.
Although African-Americans tend to be diagnosed with papillary RCC, which is a subtype of kidney cancer associated with a better survival rate as compared to clear cell RCC - a subtype of RCC more commonly diagnosed in Caucasians - they were still at a disadvantage when it comes to survival.
The study also revealed that Caucasians have a survival advantage over African-Americans in all categories except for the patients who didn't have surgical removal of the kidney. In fact, both racial groups had an equally poor prognosis of survival and were worse off than patients who had surgical procedures.
Chow noted that differences in access to health care and delayed tumor diagnosis do not appear to be the reason for the disparities as African-Americans were more likely to be diagnosed at the localized stage, and disadvantages for this racial group occurred across all tumor sizes and stages.
"A clear explanation for the disparity is not known. More research is needed to investigate reasons for the racial disparity in renal cell cancer survival," Chow noted. "We should note that survival is best in all patients when the cancer is caught early when it can be effectively removed by surgery."
Resources Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics